Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F15%3A33157502" target="_blank" >RIV/61989592:15310/15:33157502 - isvavai.cz</a>

Alternative codes found

RIV/61389030:_____/15:00448652

Result on the web

<a href="http://www.tandfonline.com/doi/full/10.1517/13543776.2015.1045414" target="_blank" >http://www.tandfonline.com/doi/full/10.1517/13543776.2015.1045414</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1517/13543776.2015.1045414" target="_blank" >10.1517/13543776.2015.1045414</a>

Result language

angličtina

Original language name

Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)

Original language description

Introduction: Cell cycle deregulation is a common characteristic of cancer cells. Progression through the cell cycle is controlled by enzymes known as cyclin-dependent kinases (CDKs), whose activity can be upregulated by a wide range of molecular mechanisms. Based on these observations, small molecule CDK inhibitors are being developed as potential cancer therapeutics. Some of these compounds have entered Phase Ill clinical trials and one of them, palbociclib, recently received accelerated approval from the FDA. However, the complexity of CDK biology and the undesired side effects of the existing inhibitors mean that the hunt for new CDK-targeting drug candidates continues. Areas covered: This article reviews patent applications related to small molecule CDK inhibitors published between 2009 and 2014. Expert opinion: Clinical trials with pan-specific inhibitors have generally yielded unambiguously positive outcomes. However, better results have been achieved with highly specific inhibitors of CDK4/CDK6. This may be due to several factors and has generated considerable interest in the discovery of new mono-specific CDK inhibitors. The development of such compounds is challenging because all CDKs have very similar active sites. Aside from this issue of selectivity, another key challenge is the identification of patients who will benefit from specific therapies.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Expert Opinion on Therapeutic Patents

ISSN

1354-3776

e-ISSN

—

Volume of the periodical

25

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

18

Pages from-to

953-970

UT code for WoS article

000361269100002

EID of the result in the Scopus database

—